Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: A number of prospective open-label studies and case reports and 1 placebo-controlled study (showing a significant effect vs. placebo on the Clinical Global Impressions-Improvement scale and positive trends in affective rating scales) suggest that the novel psychostimulant modafinil might be a useful augmentation treatment for depressive patients who are partially responsive or nonresponsive to antidepressants.1-5 This finding applies mainly to the unipolar subtype; however, a few cases of bipolar depression are reported.1-5 No switch into mania to our knowledge has been reported yet with modafinil, in contrast to other antidepressants and psychostimulants.’ ‹
Author Affiliations
Save
Share
Cite
